Jim Simons’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.3M | Sell |
533,300
-74,289
| -12% | -$5.26M | 0.06% | 424 |
|
|
2025
Q4 | $46.2M | Sell |
607,589
-319,711
| -34% | -$23.2M | 0.07% | 316 |
|
|
2025
Q3 | $56.9M | Sell |
927,300
-36,000
| -4% | -$1.88M | 0.08% | 303 |
|
|
2025
Q2 | $47M | Buy |
963,300
+293,100
| +44% | +$13.9M | 0.06% | 368 |
|
|
2025
Q1 | $34.2M | Buy |
670,200
+17,100
| +3% | +$853K | 0.05% | 453 |
|
|
2024
Q4 | $29.5M | Buy |
653,100
+114,900
| +21% | +$4.92M | 0.04% | 493 |
|
|
2024
Q3 | $20M | Sell |
538,200
-279,900
| -34% | -$9.37M | 0.03% | 668 |
|
|
2024
Q2 | $25M | Buy |
818,100
+56,700
| +7% | +$1.84M | 0.04% | 505 |
|
|
2024
Q1 | $22.1M | Buy |
761,400
+138,500
| +22% | +$3.88M | 0.03% | 583 |
|
|
2023
Q4 | $17.2M | Buy |
622,900
+388,300
| +166% | +$8.88M | 0.03% | 672 |
|
|
2023
Q3 | $5.26M | Buy |
+234,600
| New | +$8.72M | 0.01% | 1276 |
|
|
2022
Q4 | – | Sell |
-5,600
| Closed | -$281K | – | 4337 |
|
|
2022
Q3 | $281K | Buy |
+5,600
| New | +$274K | ﹤0.01% | 3242 |
|
|
2022
Q1 | – | Sell |
-22,000
| Closed | -$876K | – | 4377 |
|
|
2021
Q4 | $876K | Sell |
22,000
-59,600
| -73% | -$2.28M | ﹤0.01% | 2747 |
|
|
2021
Q3 | $3.04M | Sell |
81,600
-123,410
| -60% | -$5.07M | ﹤0.01% | 1777 |
|
|
2021
Q2 | $8.67M | Buy |
205,010
+13,810
| +7% | +$592K | 0.01% | 1280 |
|
|
2021
Q1 | $9.05M | Buy |
+191,200
| New | +$11.4M | 0.01% | 1263 |
|
|
2020
Q3 | – | Sell |
-5,200
| Closed | -$264K | – | 3619 |
|
|
2020
Q2 | $264K | Sell |
5,200
-374,200
| -99% | -$18.4M | ﹤0.01% | 3087 |
|
|
2020
Q1 | $16.9M | Buy |
379,400
+65,500
| +21% | +$3.3M | 0.02% | 863 |
|
|
2019
Q4 | $15.1M | Buy |
313,900
+183,600
| +141% | +$7.8M | 0.01% | 1175 |
|
|
2019
Q3 | $4.41M | Sell |
130,300
-238,760
| -65% | -$10.4M | ﹤0.01% | 1864 |
|
|
2019
Q2 | $16.6M | Sell |
369,060
-538,240
| -59% | -$21.3M | 0.01% | 1080 |
|
|
2019
Q1 | $34.2M | Sell |
907,300
-115,400
| -11% | -$3.87M | 0.03% | 700 |
|
|
2018
Q4 | $35.1M | Buy |
1,022,700
+740,100
| +262% | +$26.6M | 0.04% | 578 |
|
|
2018
Q3 | $13.3M | Buy |
+282,600
| New | +$11.7M | 0.01% | 1169 |
|
|
2018
Q2 | – | Sell |
-219,200
| Closed | -$5.93M | – | 3473 |
|
|
2018
Q1 | $5.93M | Sell |
219,200
-7,400
| -3% | -$187K | 0.01% | 1708 |
|
|
2017
Q4 | $3.78M | Buy |
+226,600
| New | +$3.84M | ﹤0.01% | 1979 |
|
|
2016
Q4 | – | Sell |
-552,700
| Closed | -$7.74M | – | 3401 |
|
|
2016
Q3 | $7.74M | Buy |
552,700
+450,800
| +442% | +$3.66M | 0.01% | 1324 |
|
|
2016
Q2 | $715K | Sell |
101,900
-846,800
| -89% | -$6.21M | ﹤0.01% | 2665 |
|
|
2016
Q1 | $6.11M | Buy |
+948,700
| New | +$16.5M | 0.01% | 1481 |
|
|
2015
Q4 | – | Sell |
-65,900
| Closed | -$1.76M | – | 3397 |
|
|
2015
Q3 | $1.76M | Buy |
+65,900
| New | +$2.82M | ﹤0.01% | 2073 |
|
|
2014
Q3 | – | Sell |
-21,600
| Closed | -$565K | – | 2932 |
|
|
2014
Q2 | $565K | Buy |
+21,600
| New | +$462K | ﹤0.01% | 2276 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Jim Simons's PTCT Position: Q1 2026 in Review
Jim Simons reduced its PTC Therapeutics (PTCT) stake by 12% in Q1 2026, selling an estimated $5.26M and leaving 533,300 shares worth $36.3M. The position accounts for 0.06% of the portfolio, ranked #424.
Jim Simons first reported a position in PTCT in Q2 2014 and has held it in 31 quarters since. The position peaked at $56.9M in Q3 2025. 351 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Jim Simons held 533,300 shares of PTC Therapeutics worth $36.3M as of Q1 2026.
- Jim Simons sold 74,289 PTC Therapeutics shares in Q1 2026, an estimated $5.26M.
- PTC Therapeutics made up 0.06% of Jim Simons's portfolio in Q1 2026, its #424 holding.
- Jim Simons first reported a position in PTC Therapeutics in Q2 2014 and has held it in 31 quarters since.
- Jim Simons's PTC Therapeutics position peaked at $56.9M in Q3 2025.
- 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.